Search hospitals > Wisconsin > Milwaukee
Children's Hospital of Wisconsin
Claim this profileMilwaukee, Wisconsin 53226
Global Leader in Cancer
Global Leader in Adult T-Cell Leukemia/Lymphoma
Conducts research for Relapse
Conducts research for Lymphoma
Conducts research for Brain Tumor
414 reported clinical trials
26 medical researchers
Summary
Children's Hospital of Wisconsin is a medical facility located in Milwaukee, Wisconsin. This center is recognized for care of Cancer, Adult T-Cell Leukemia/Lymphoma, Relapse, Lymphoma, Brain Tumor and other specialties. Children's Hospital of Wisconsin is involved with conducting 414 clinical trials across 704 conditions. There are 26 research doctors associated with this hospital, such as Paul D. Harker-Murray, Meghen B. Browning, Michael Burke, MD, and Julie-An Talano.Area of expertise
1Cancer
Global LeaderStage IV
Stage I
Stage II
2Adult T-Cell Leukemia/Lymphoma
Global LeaderStage IV
Philadelphia chromosome positive
Stage II
Top PIs
Paul D. Harker-MurrayChildren's Hospital of Wisconsin8 years of reported clinical research
Expert in Cystic Tumor
Expert in Brain Tumor
19 reported clinical trials
26 drugs studied
Meghen B. BrowningChildren's Hospital of Wisconsin19 years of reported clinical research
Studies Cancer
Studies Neuroblastoma
16 reported clinical trials
40 drugs studied
Michael Burke, MDChildren's Hospital of Wisconsin2 years of reported clinical research
Expert in Adult T-Cell Leukemia/Lymphoma
Studies Acute Lymphoblastic Leukemia
14 reported clinical trials
43 drugs studied
Julie-An TalanoChildren's Hospital of Wisconsin6 years of reported clinical research
Studies Acute Lymphoblastic Leukemia
Studies Lymphoid Hematopoietic Disease
9 reported clinical trials
17 drugs studied
Clinical Trials running at Children's Hospital of Wisconsin
Acute Lymphoblastic Leukemia
Adult T-Cell Leukemia/Lymphoma
Testicular cancer
Lymphoma
Primary Immunodeficiency
Cancer
Lymphoid Hematopoietic Disease
Leukemia
Retinoblastoma
Acute Myeloid Leukemia
Levocarnitine
for Chemotherapy-Related Liver Protection in Leukemia and Lymphoma
This phase III trial compares the effect of adding levocarnitine to standard chemotherapy versus (vs.) standard chemotherapy alone in protecting the liver in patients with leukemia or lymphoma. Asparaginase is part of the standard of care chemotherapy for the treatment of acute lymphoblastic leukemia (ALL), lymphoblastic lymphoma (LL), and mixed phenotype acute leukemia (MPAL). However, in adolescent and young adults (AYA) ages 15-39 years, liver toxicity from asparaginase is common and often prevents delivery of planned chemotherapy, thereby potentially compromising outcomes. Some groups of people may also be at higher risk for liver damage due to the presence of fat in the liver even before starting chemotherapy. Patients who are of Japanese descent, Native Hawaiian, Hispanic or Latinx may be at greater risk for liver damage from chemotherapy for this reason. Carnitine is a naturally occurring nutrient that is part of a typical diet and is also made by the body. Carnitine is necessary for metabolism and its deficiency or absence is associated with liver and other organ damage. Levocarnitine is a drug used to provide extra carnitine. Laboratory and real-world usage of the dietary supplement levocarnitine suggests its potential to prevent or reduce liver toxicity from asparaginase. The overall goal of this study is to determine whether adding levocarnitine to standard of care chemotherapy will reduce the chance of developing severe liver damage from asparaginase chemotherapy in ALL, LL and/or MPAL patients.
Recruiting2 awards Phase 3
Blinatumomab + HCT
for Acute Lymphoblastic Leukemia
This trial will assess the feasibility of alpha/beta T-cell and B-cell depleted allogeneic hematopoietic cell transplantation (HCT) followed by blinatumomab therapy for high-risk B cell acute lymphoblastic leukemia (ALL) as a means of reducing rates of subsequent relapse and improving survival, while also minimizing treatment-related morbidity/ mortality and late effects. The conditioning regimens will be dependent on the patient's minimal residual disease (MRD) status prior to HCT using high throughput sequencing.
Recruiting2 awards Phase 214 criteria
Inotuzumab Ozogamicin
for Acute Lymphoblastic Leukemia
This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. This trial also studies the outcomes of patients with mixed phenotype acute leukemia (MPAL), and B-lymphoblastic lymphoma (B-LLy) when treated with ALL therapy without inotuzumab ozogamicin. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer cells in a targeted way and delivers calicheamicin to kill them. Other drugs used in the chemotherapy regimen, such as cyclophosphamide, cytarabine, dexamethasone, doxorubicin, daunorubicin, methotrexate, leucovorin, mercaptopurine, prednisone, thioguanine, vincristine, and pegaspargase or calaspargase pegol work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial will also study the outcomes of patients with mixed phenotype acute leukemia (MPAL) and disseminated B lymphoblastic lymphoma (B-LLy) when treated with high-risk ALL chemotherapy. The overall goal of this study is to understand if adding inotuzumab ozogamicin to standard of care chemotherapy maintains or improves outcomes in High Risk B-cell Acute Lymphoblastic Leukemia (HR B-ALL). The first part of the study includes the first two phases of therapy: Induction and Consolidation. This part will collect information on the leukemia, as well as the effects of the initial treatment, to classify patients into post-consolidation treatment groups. On the second part of this study, patients with HR B-ALL will receive the remainder of the chemotherapy cycles (interim maintenance I, delayed intensification, interim maintenance II, maintenance), with some patients randomized to receive inotuzumab. The patients that receive inotuzumab will not receive part of delayed intensification. Other aims of this study include investigating whether treating both males and females with the same duration of chemotherapy maintains outcomes for males who have previously been treated for an additional year compared to girls, as well as to evaluate the best ways to help patients adhere to oral chemotherapy regimens. Finally, this study will be the first to track the outcomes of subjects with disseminated B-cell Lymphoblastic Leukemia (B-LLy) or Mixed Phenotype Acute Leukemia (MPAL) when treated with B-ALL chemotherapy.
Recruiting2 awards Phase 3
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Children's Hospital of Wisconsin?
Where is Children's Hospital of Wisconsin located?
Who should I call to ask about financial aid or insurance network?
What insurance does Children's Hospital of Wisconsin accept?
What awards or recognition has Children's Hospital of Wisconsin received?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.